Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases
Latest Information Update: 01 Jan 2021
At a glance
- Drugs TriMix-MEL (Primary) ; TriMix-MEL (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms DCMEL
- 01 Dec 2020 Due to a lack of financial means to continue the study, patient recruitment was interrupted in October 2014. One year later, following an interim analysis with a minimal follow-up of 1 year for all randomized patients, it was decided to permanently stop the recruitment of patients as per the results published in the Cancer Immunology Immunotherapy.
- 01 Dec 2020 Results published in the Cancer Immunology Immunotherapy
- 01 Dec 2020 Status changed from completed to discontinued as per the results published in the Cancer Immunology Immunotherapy.